Literature DB >> 18837784

The structural immunology of antibody protection against West Nile virus.

Michael S Diamond1, Theodore C Pierson, Daved H Fremont.   

Abstract

SUMMARY: Recent investigations of the interaction between the West Nile virus (WNV) envelope protein (E) and monoclonal antibodies (mAbs) have elucidated fundamental insights into the molecular mechanisms of neutralization. Structural studies have defined an epitope on the lateral ridge of domain III (DIII-lr) of the WNV E protein that is recognized by antibodies with the strongest neutralizing activity in vitro and in vivo. Antibodies that bind this epitope are highly potent because they efficiently block at a post-entry step of viral infection with relatively low virion occupancy requirements. In this review, we discuss the structural, molecular, and immunologic basis for antibody-mediated protection against WNV, and its implications for novel therapeutic or vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837784      PMCID: PMC2646609          DOI: 10.1111/j.1600-065X.2008.00676.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  138 in total

1.  Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence.

Authors:  Brian C Keller; Brenda L Fredericksen; Melanie A Samuel; Richard E Mock; Peter W Mason; Michael S Diamond; Michael Gale
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 2.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  The DE loop of the domain III of the envelope protein appears to be associated with West Nile virus neutralization.

Authors:  Kang-Seuk Choi; Jin-Ju Nah; Young-Joon Ko; Yong-Joo Kim; Yi-Seok Joo
Journal:  Virus Res       Date:  2006-10-05       Impact factor: 3.303

4.  The morphological and biological effects of various antisera on avian infectious bronchitis virus.

Authors:  D M Berry; J D Almeida
Journal:  J Gen Virol       Date:  1968-07       Impact factor: 3.891

5.  Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis.

Authors:  Melanie A Samuel; John D Morrey; Michael S Diamond
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

Review 6.  West Nile virus neuroinvasive disease.

Authors:  Larry E Davis; Roberta DeBiasi; Diane E Goade; Kathleen Y Haaland; Jennifer A Harrington; JoAnn B Harnar; Steven A Pergam; Molly K King; B K DeMasters; Kenneth L Tyler
Journal:  Ann Neurol       Date:  2006-09       Impact factor: 10.422

7.  Murine model for dengue virus-induced lethal disease with increased vascular permeability.

Authors:  Sujan Shresta; Kristin L Sharar; Daniil M Prigozhin; P Robert Beatty; Eva Harris
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

8.  Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.

Authors:  Karin Stiasny; Stefan Kiermayr; Heidemarie Holzmann; Franz X Heinz
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

9.  Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion.

Authors:  S B Halstead
Journal:  Yale J Biol Med       Date:  1970-04

10.  Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway.

Authors:  N R Cooper; F C Jensen; R M Welsh; M B Oldstone
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  67 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

2.  Positive selection sites in the surface genes of dengue virus: phylogenetic analysis of the interserotypic branches of the four serotypes.

Authors:  Patsarin Rodpothong; Prasert Auewarakul
Journal:  Virus Genes       Date:  2012-01-06       Impact factor: 2.332

3.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

Review 4.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

5.  Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Authors:  Orly Gershoni-Yahalom; Shimon Landes; Smadar Kleiman-Shoval; David Ben-Nathan; Michal Kam; Bat-El Lachmi; Yevgeny Khinich; Michael Simanov; Itzhak Samina; Anat Eitan; Irun R Cohen; Bracha Rager-Zisman; Angel Porgador
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

6.  Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E.

Authors:  Stefan Kiermayr; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 7.  West Nile virus: A re-emerging pathogen revisited.

Authors:  Miguel A Martín-Acebes; Juan-Carlos Saiz
Journal:  World J Virol       Date:  2012-04-12

Review 8.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

9.  West nile virus: characteristics of an african virus adapting to the third millennium world.

Authors:  Marina Monini; Emiliana Falcone; Luca Busani; Roberto Romi; Franco Maria Ruggeri
Journal:  Open Virol J       Date:  2010-04-22

10.  Virus and host determinants of West Nile virus pathogenesis.

Authors:  Michael S Diamond
Journal:  PLoS Pathog       Date:  2009-06-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.